NCT05362786View on ClinicalTrials.gov

Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 24, 2024

Study Completion Date

July 24, 2024

Conditions
Chronic Kidney Diseases
Interventions
DRUG

Allogeneic adipose-derived mesenchymal stem cells (MSC)

Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84

DRUG

Allogeneic adipose-derived mesenchymal stem cells (MSC)

Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0

Trial Locations (2)

32224

Mayo Clinic Florida, Jacksonville

55905

Mayo Clinic Rochester, Rochester

All Listed Sponsors
lead

LaTonya J. Hickson

OTHER